Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

After shares of Novo Nordisk (NVO) fell throughout the last year, the more recent drop may be its last. The company, along with its rival Eli Lilly (LLY), will offer its obesity drug for $499 per ...

Hims & Hers Health ($HIMS) stock declined 2% on Monday after rival GoodRx Holdings ($GDRX) announced a deal with Novo Nordisk ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Meta (META) stock is dipping on reports that the company is restructuring its artificial intelligence (AI) unit for the ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

GoodRx (NASDAQ:GDRX) jumped 18% after revealing a partnership with Novo Nordisk (NYSE:NVO) to offer Ozempic and Wegovy to ...